anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Both ketoconazole and posaconazole are FDA-approved anti-fungal agents with a well-established side effect and safety profile. Ketoconazole and posaconazole have shown efficacy in reducing tumor cell proliferation in in-vitro studies. Furthermore, both have also shown efficacy, mediated at least in part through inhibition of HK2 activity, in animal models with dosing concentration and schedules that are documented as safe in humans. As a drug, posaconazole has a more predictable half-life than ketoconazole and has less off-target effects. Therefore, the proposed trial will focus on the role of posaconazole exclusively. As a first step, demonstration of adequate penetrance of study drug in brain and tumor tissue (pharmacokinetics) and biological effect (inhibition of glycolysis and subsequent tumor cell death) is necessary prior to large scale clinical studies. A total of 5 control participants will be included in this study as the investigator specifically wants to assess for pharmacodynamic differences too. The addition of a control group to this study rather to both the studies (ketoconazole study is a separate protocol) is because the investigator feels posaconazole may be a more promising drug for moving forward.

Plasma drug concentration measurements are an unreliable method to assess delivery of drugs across the blood-brain barrier. In contrast, intracerebral MDC monitoring allows for approximate measurements within extracellular fluid (ECF) sampling of the brain. MDC placement within the brain is not a novel technique and has been utilized routinely in the ICU setting to measure brain metabolism by sampling of ECF of traumatic brain injury patients \[59-61\].

MDC are now FDA-approved and are being placed routinely with intracranial pressure monitors. This method allows for continuous measurement of ECF within a tumor or normal tissue. The dialysis probe has a semipermeable membrane which is less than 1 mm in diameter into which two sections of microcatheter are fused. Previous studies have demonstrated the feasibility of keeping the catheters in place of critically injured patients for up to 2 weeks \[62-64\].

When placed at the time of surgical resection, the microcatheters are stereotactically implanted, placing the probe within the desired brain and/or tumor region. Externally, the catheter is connected to a syringe pump, which delivers a low flow rate (μl/min) of continuous perfusion fluid (Lactated Ringers or artificial CSF) and dialysate is collected in a microvial from the outlet tube. This sterile, single use catheter is minimally invasive and developed to achieve optimal diffusing characteristics similar to passive diffusion of a capillary blood vessel. Just as in the function of brain capillary vessel, water, inorganic ions and small organic molecules freely diffuse across the membrane of the probe, whereas proteins and protein bound compounds are impermeable. Additionally, lipophilic compounds are poorly recovered. Therefore, assessment of pharmacokinetics of drug using MDC provides valuable insight relevant to its anti-neoplastic properties.
RAPAFLO is the brand name for silodosin, a selective antagonist of alpha-1 adrenoreceptors. The chemical name of silodosin is 1-(3-Hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide and the molecular formula is C25H32F3N3O4 with a molecular weight of 495.53. The structural formula of silodosin is:

Silodosin is a white to pale yellowish white powder that melts at approximately 105 to 109°C. It is very soluble in acetic acid, freely soluble in alcohol, and very slightly soluble in water.

Each RAPAFLO 8 mg capsule for oral administration contains 8 mg silodosin, and the following inactive ingredients: D-mannitol, magnesium stearate, pregelatinized starch, and sodium lauryl sulfate. The size #1 hard gelatin capsules contain gelatin and titanium dioxide. The capsules are printed with edible ink containing FD&C Blue No. 1 Aluminum Lake and yellow iron oxide.

Each RAPAFLO 4 mg capsule for oral administration contains 4 mg silodosin, and the following inactive ingredients: D-mannitol, magnesium stearate, pregelatinized starch, and sodium lauryl sulfate. The size #3 hard gelatin capsules contain gelatin and titanium dioxide. The capsules are printed with edible ink containing yellow iron oxide.
This is a single dose escalating study. On enrolment into the study, each subject will be assigned to a group. These groups will be aligned to specific dose levels of GSK1070806. All subjects will be randomised to receive either a single intravenously administered dose of GSK1070806 or matching placebo (saline). The randomisation is generated by GSK prior to study start.
PURPOSE: To provide a novel compd. which has an excellent pharmacological activity and is useful e.g. as a remedy for hypercalcemic diseases, Paget's diseases, etc., and as an inhibitor aganist ovulation or spermatogenesis.  
     CONSTITUTION: This compd. is an LHRH antagonist peptide having, in the form of being combined with amino groups, a sugar residue (A) and a residue of (B) formula I (wherein Y 1  and Y 2  are both H or either one is H and the other is OH; and f and g are each 0 or 1) or formula II or a physiologically tolerable ether or ester thereof (provided when the LHRH antagonist peptide has residue A, then this residue is an Amadori sugar residue attached by a coupling other than a direct N-glycosidic bond to an ω-amino group of an ω-amino-substd. side chain at the 8 position) in free form or in salt or complex form. An example is a compd. of formula III. The compd. having a residue of formula I is obtd. by reducively aminating a compd. of formula IV (wherein Z 4  is -CHO or the like) with a compd. of the formula: P-NH 2  (wherein P is an LHRH antagonist residue or the like) to give an isomer mixture and separating and recovering an optically active isomer from the isomer mixture. 
     COPYRIGHT: (C)1995,JPO
Typically Developing Children The second group will consist of 30 children with typically developing who were between ages 3 and 10 years. The Sensory Profile will used to evaluate sensory processing. This questionnaire will be completed by parents who record a child's responses to sensory events in daily life.
This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of Prevnar 13™ vaccine, co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of Prevnar 13™ and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for Prevnar 13™ and on the right side for Infanrix hexa™.
A system for identifying and ameliorating body degradations, the system comprising a computing device, wherein the computing device is configured to receive biological extraction data. Computing device may generate, as a function of a degradation machine-learning model and the biological extraction data, a degradation profile. Computing device may calculate a biological degradation function that is a mathematical function that describes the change in rate of degradation over time corresponding to the user. Computing device may identify, using a degradation imbalance machine-learning process and the degradation profile, a degradation imbalance. Computing device may determine, as a function of the degradation imbalance machine-learning process and the degradation imbalance, a degradation antidote strategy to decrease the rate of biological degradation of a user by performing a simulation. Computing device may display to a user the degradation antidote strategy and a degradation prevention instruction set for a user to alter degradation rates.
The invention discloses three schisandra chinensis extracts and a preparation process and application thereof, belonging to the technical field of medicines. The preparation method of the schisandra extract comprises the following steps: processing fructus Schisandrae chinensis with CSFE method to obtain extract A, standing at room temperature for layering to obtain extract B (rich in schisandrin B) and extract C (rich in schisandrin A). Decocting the residue with water, adding beta-cyclodextrin into the filtrate to clathrate and adsorb residual liposoluble active ingredients in the residue, and filtering to obtain clathrate and adsorbed lignan. Concentrating the filtrate, precipitating with ethanol to obtain fructus Schisandrae polysaccharide. Mixing the inclusion adsorption lignan and polysaccharide with the extract A, B, C to obtain extract I, extract II and extract III. The effective components of the three extracts account for more than 50% of the extracts, and comprise three active ingredients of total lignan, linoleic acid and polysaccharide, wherein the total lignan accounts for 18-25%. The three extracts have different proportions of ethyl and methanol, and can be used for developing different new medicines respectively for treating depression, sleep improving, intelligence improving, etc.
An injectable iron preparation is obtained by the reaction of an iron salt such as ferric chloride or ferric nitrate or of ferric oxychloride or of dialysed iron with a synthetic polysaccharide such as polyglucose or polygalactose in an alkaline medium.  The ratio of the weight of the polysaccharde to the weight of iron is preferably from 10-20 : 1.  The polysaccharide may be obtained by heating glucose or galactose with an acid catalyst until the resulting polysaccharide possesses only 5% and 1% respectively of the reducing value of the original sugar.  It is then dissolved in water and the iron salt or dialysed iron added and then sufficient caustic soda solution added to produce a pH of about 11, and then the mixture heated to 100 DEG C. for about two hours.  It is then cooled and methanol, ethanol, or acetone added and the precipitate removed.  The injectable solution may contain 5- 1/4 % of iron.ALSO:An injectable iron preparation is obtained by the reaction of an iron salt such as ferric chloride or ferric nitrate or of ferric oxychloride or of dialysed iron with a synthetic polysaccharide such as polyglucose or polygalactose in an alkaline medium.  The ratio of the weight of the polysaccharide to the weight of iron is preferably from 10 to 20 : 1. The polysaccharide may be obtained by heating glucose or galactose with an acid catalyst until the resulting polysaccharide possesses only 5% and 1% respectively of the reducing value of the original sugar.  It is then dissolved in water and the iron salt or dialysed iron added and then sufficient caustic soda solution added to produce a pH of about 11, and then the mixture heated to 100 DEG  C. for about two hours.  It is then cooled and methanol ethanol or acetone added and the precipitate removed.  The injectable solution may contain 5-7 1/4 % of iron.
Participants have Advanced or Metastatic Clear Cell Renal Cell Carcinoma/RCC. The protocol will start with a safety-lead in phase using a 3+3 design to establish the maximal tolerated dose (MTD) of 177Lu-labeled-girentuximab in combination with standard-dose nivolumab. The initial starting dose of 177Lu-labeled-girentuximab is 1804 MBq/m2 which is 75% of the single agent dose established in prior studies and will proceed as shown in the schema below. Once the MTD is established, a Simon two-stage optimal design will commence. 10 patients will be enrolled in the first stage and if no responses are observed, the study will be terminated. If 1 or more responses are observed in the first 10 patients, we will extend enrollment to a total of 29 patients (19 additional patients) in the second stage.
Mother-child whose care course for the child's congenital axial tumor included treatment at the AP-HP between 2010 and 2021. Fetus presenting a malignant or benign solid tumor of thoracic, abdominal or pelvic location and whose clinico-radiological or histological diagnosis is confirmed postnatally up to 1 year of life with the onset of symptoms in the first three months of life.
Aerosol ointment compositions are provided that, when a deposit is expelled from an aerosol container containing the composition onto damaged tissue, there is applied to the tissue a cold ointment which exerts a cooling pain relief effect and a medicinal therapeutic effect on the tissue. Examples of typical ointments of the invention are those for the temporary relief of hemorrhoids, treatment of sunburn and relief from arthritic pain. A method is provided for the manufacture of an aerosol ointment composition that is capable of expelling from an aerosol container an ointment that exerts on damaged tissues both a pain relieving cooling effect and a medicinal therapeutic effect. The aerosol composition enhances the therapeutic action of an ointment by instantly producing a sustained cooling effect which provides fast relief from pain and itching as well as a tendency to shrink swollen, inflamed tissue in advance of the slower action of any medication present in the ointment. The aerosol composition consists of from about 10 to about 60 percent by weight of ingredients of an ointment that is an oil-in-water emulsion and from about 40 to about 90 percent by weight of liquefied propellant that is predominantly a non-polar propellant. The sum of the ointment ingredients and the propellant equals 100 percent by weight of the composition.
There will be 3 Vojta therapy sessions conducted on 2 consecutive weeks with an interval of 7 dayssessions, on 1st, 7th and 14th days. Each session will consist of a 45-minute Vojta thera between py protocol based on three exercises, 15 minutes per exercise: Crawling Réflex, and 1st phase and 2nd phase Rolling reflex. The relative or close person will be instructed to carry out an exercise protocol to do at home every day for 20 minutes during the 2-week study. All interventions will be made by the principal investigator.
Clobetasol propionate foam can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. This may occur during treatment or after withdrawal of treatment. Factors that predispose a patient to HPA axis suppression include the use of high-potency steroids, large treatment surface areas, prolonged use, use of occlusive dressings, altered skin barrier, liver failure, and young age. Evaluation for HPA axis suppression may be done by using the adrenocorticotropic hormone (ACTH) stimulation test.

In a trial evaluating the effects of clobetasol propionate foam on the HPA axis, 13 subjects applied clobetasol propionate foam to at least 20% of involved body surface area for 14 days. HPA axis suppression was identified in 5 out of 13 subjects (38%) [ see Clinical Pharmacology (12.2)] .

If HPA axis suppression is documented, gradually withdraw the drug, reduce the frequency of application, or substitute with a less potent corticosteroid.

Cushing's syndrome and hyperglycemia may also occur due to the systemic effects of the topical corticosteroid. These complications are rare and generally occur after prolonged exposure to excessively large doses, especially of high-potency topical corticosteroids.

Pediatric patients may be more susceptible to systemic toxicity due to their larger skin surface to body mass ratios [ see Use in Specific Populations (8.4)].
PURPOSE/OBJECTIVES: Biomarkers for extracranial oligometastatic disease remain elusive and few studies have attempted to correlate genomic data to the presence of true oligometastatic disease.
METHODS: Patients with non-small cell lung cancer (NSCLC) and brain metastases were identified in our departmental database. Electronic medical records were used to identify patients for whom liquid biopsy-based comprehensive genomic profiling (Guardant Health) was available. Extracranial oligometastatic disease was defined as patients having ≤5 non-brain metastases without diffuse involvement of a single organ. Widespread disease was any spread beyond oligometastatic. Fisher's exact tests were used to screen for mutations statistically associated (p<0.1) with either oligometastatic or widespread extracranial disease. A risk score for the likelihood of oligometastatic disease was generated and correlated to the likelihood of having oligometastatic disease vs widespread disease. For oligometastatic patients, a competing risk analysis was done to assess for cumulative incidence of oligometastatic progression. Cox regression was used to determine association between oligometastatic risk score and oligoprogression.
RESULTS: 130 patients met study criteria and were included in the analysis. 51 patients (39%) had extracranial oligometastatic disease. Genetic mutations included in the Guardant panel that were associated (p<0.1) with the presence of oligometastatic disease included ATM, JAK2, MAP2K2, and NTRK1, while ARID1A and CCNE1 were associated with widespread disease. Patients with a positive, neutral and negative risk score for oligometastatic disease had a 78%, 41% and 11.5% likelihood of having oligometastatic disease, respectively (p<0.0001). Overall survival for patients with positive, neutral and negative risk scores for oligometastatic disease was 86% vs 82% vs 64% at 6 months (p=0.2). Oligometastatic risk score was significantly associated with the likelihood of oligoprogression based on the Wald chi-square test. Patients with positive, neutral and negative risk scores for oligometastatic disease had a cumulative incidence of oligometastatic progression of 77% vs 35% vs 33% at 6 months (p=0.03).
CONCLUSIONS: Elucidation of a genomic signature for extracranial oligometastatic disease derived from non-invasive liquid biopsy appears feasible for NSCLC patients. Patients with this signature exhibited higher rates of early oligoprogression. External validation could lead to a biomarker that has the potential to direct local therapies in oligometastatic patients.
In vivo drug interaction studies have demonstrated a lack of a significant drug interaction between leflunomide and tri-phasic oral contraceptives, and cimetidine.

In vitro studies of protein binding indicated that warfarin did not affect M1 protein binding. At the same time M1 was shown to cause increases ranging from 13 to 50% in the free fraction of diclofenac, ibuprofen and tolbutamide at concentrations in the clinical range. In vitro studies of drug metabolism indicate that M1 inhibits CYP 450 2C9, which is responsible for the metabolism of phenytoin, tolbutamide, warfarin and many NSAIDs. M1 has been shown to inhibit the formation of 4’-hydroxydiclofenac from diclofenac in vitro. The clinical significance of these findings with regard to phenytoin and tolbutamide is unknown; however, there was extensive concomitant use of NSAIDs in the clinical studies and no differential effect was observed (see PRECAUTIONS: Drug Interactions).

### Methotrexate

Co-administration, in 30 patients, of leflunomide (100 mg/day x 2 days followed by 10 to 20 mg/day) with methotrexate (10 to 25 mg/week, with folate) demonstrated no pharmacokinetic interaction between the two drugs. However, co-administration increased risk of hepatotoxicity (see PRECAUTIONS: Drug Interactions: Hepatotoxic Drugs).

### Rifampin

Following concomitant administration of a single dose of leflunomide to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~ 40%) over those seen when leflunomide was given alone. Because of the potential for leflunomide levels to continue to increase with multiple dosing, caution should be used if patients are to receive both leflunomide and rifampin.
The preparation of cosmetic composition for conditioning colored products (P1, P2), comprises selecting an enclosure among several enclosures containing different products, and circulating water through enclosures to collect a solution of the composition. The enclosures are arranged on an extractor and forming a part of a refill. The water simultaneously/non-simultaneously circulates in several enclosures. The water is injected under vapor and liquid phase in enclosures using injectors in which a temperature of the water is higher than 80[deg]C and a pressure is 10 bars. The preparation of cosmetic composition for conditioning colored products (P1, P2), comprises selecting an enclosure among several enclosures containing different products, and circulating water through enclosures to collect a solution of the composition. The enclosures are arranged on an extractor and forming a part of a refill. The water simultaneously/non-simultaneously circulates in several enclosures. The water is injected under vapor and liquid phase in enclosures using injectors in which a temperature of the water is higher than 80[deg]C and a pressure is 10 bars. Before selecting the enclosure, a color of person is analyzed to test with the cosmetic composition. The selection is carried out on the basis of the color. The enclosures comprise a keratin-coloring agent. The solution resulting from the extraction is collected in a container. The container comprises a compound to be mixed with the solution. The enclosures are partially defined by a first wall through which the injector is passed and a second wall to disperse the water in the enclosure under a pressure. Independent claims are included for: (1) an unit for preparing cosmetic composition; (2) an extraction apparatus; and (3) a refill.